TTR and amyloidosis: It is particularly worth mentioning that in 2018, the first RNAi-based therapeutic drug patisiran (Onpattro®), a lipid-based system aimed at triggering TTR gene silencing in patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), was approved by the FDA, which is promising news [5,6].